PDCD1 and non-small cell lung carcinoma: To further assess the predictive value of LM in patients with advanced NSCLC, we identified a total of 182 NSCLC patients received PD-1/PD-L1 monotherapy from January 1, 2016 to November 1, 2020 in two medical centers.